Citadel Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Citadel Advisors’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.24M	Sell	73,600 -34,200	-32%	-$1.13M	﹤0.01%	5851
2025 Q4	$3.87M	Sell	107,800 -43,900	-29%	-$1.34M	﹤0.01%	4723
2025 Q3	$3.66M	Buy	151,700 +109,400	+259%	+$2.29M	﹤0.01%	4932
2025 Q2	$624K	Buy	42,300 +31,800	+303%	+$370K	﹤0.01%	8116
2025 Q1	$100K	Sell	10,500 -10,100	-49%	-$106K	﹤0.01%	11464
2024 Q4	$256K	Sell	20,600 -11,700	-36%	-$120K	﹤0.01%	9977
2024 Q3	$315K	Buy	32,300 +2,400	+8%	+$28.1K	﹤0.01%	9235
2024 Q2	$482K	Buy	29,900 +26,900	+897%	+$485K	﹤0.01%	8128
2024 Q1	$64.3K	Buy	+3,000	New	+$56.4K	﹤0.01%	11924

Other funds holding INDV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's INDV Position: Q1 2026 in Review

Citadel Advisors increased its Indivior Pharmaceuticals (INDV) stake by 17% in Q1 2026, buying an estimated $16.9M and bringing the position to 3,574,044 shares worth $109M. The position accounts for 0.02% of the portfolio, ranked #755.

Citadel Advisors first reported a position in INDV in Q1 2024 and has held it in 9 quarters since. The position peaked at $110M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

Citadel Advisors held 3,574,044 shares of Indivior Pharmaceuticals worth $109M as of Q1 2026.
Citadel Advisors bought 512,142 Indivior Pharmaceuticals shares in Q1 2026, an estimated $16.9M.
Indivior Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #755 holding.
Citadel Advisors first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Citadel Advisors's Indivior Pharmaceuticals position peaked at $110M in Q4 2025.
289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.